Education
About Us
Working with TipRanks
Follow Us
aXichem AB Class A (DE:A6X)
FRANKFURT:A6X
A6X Stock Chart & Stats
€0.21
<€0.01(1.32%)
At close: 4:00 PM EST
€0.21
<€0.01(1.32%)
Day’s Range― - ―
52-Week Range€0.06 - €0.32
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.40M
Enterprise Value€111.27M
Total Cash (Recent Filing)€6.78M
Total Debt (Recent Filing)€3.09M
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Feb 26, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding59,114,906
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.89
Price to Sales (P/S)7.31
P/FCF Ratio-5.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsAn ~83% gross margin indicates the product technology commands strong per-unit economics in specialty chemical/animal nutrition end-markets. High gross margins create durable opportunity for operating leverage as revenue scales, improving the pathway to sustained profitability if SG&A and R&D are controlled.
Revenue Growth TractionPositive ~15% YoY revenue growth shows commercial adoption beyond pilot stages and validates market demand for phenylcapsaicin applications. If this trend continues, it supports leveraging fixed costs and improving operating margins over the next several quarters as product placements expand in animal nutrition.
Debt-free Balance Sheet And Equity BaseA debt-free balance sheet and ~70.1M equity provide structural financial flexibility to fund commercialization and R&D without immediate refinancing pressure. This reduces solvency risk and gives management time to reach cash break-even or raise capital on more favorable terms over 2–6 months.
Bears Say
Deep And Persistent UnprofitabilityA net margin near -208% and negative EBIT/EBITDA reflect a cost base far exceeding current revenues. Absent rapid revenue scale or cost restructuring, persistent losses can erode equity, limit reinvestment capacity, and force dilutive financings, threatening long-term viability if profitability remains out of reach.
Consistent Negative Operating And Free Cash FlowOngoing negative OCF and FCF (~-11.5M) mean operations do not self-fund growth, creating reliance on external funding or reserves. Over a multi-month horizon this raises dilution and execution risk, as sustained cash burn can constrain commercialization investments and slow market expansion.
Negative Returns On EquityA ~-25% ROE signals the company is destroying shareholder capital rather than creating it. Persistently negative ROE undermines investor confidence and can make future capital raises more costly, limiting ability to scale operations and commercialize products without significant strategic change.
aXichem AB Class A News
A6X FAQ
What was aXichem AB Class A’s price range in the past 12 months?
aXichem AB Class A lowest stock price was €0.06 and its highest was €0.32 in the past 12 months.
What is aXichem AB Class A’s market cap?
aXichem AB Class A’s market cap is €10.40M.
When is aXichem AB Class A’s upcoming earnings report date?
aXichem AB Class A’s upcoming earnings report date is Feb 26, 2026 which is in 21 days.
How were aXichem AB Class A’s earnings last quarter?
aXichem AB Class A released its earnings results on Nov 28, 2025. The company reported -€0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.014.
Is aXichem AB Class A overvalued?
According to Wall Street analysts aXichem AB Class A’s price is currently Overvalued.
Does aXichem AB Class A pay dividends?
aXichem AB Class A does not currently pay dividends.
What is aXichem AB Class A’s EPS estimate?
aXichem AB Class A’s EPS estimate is -0.01.
How many shares outstanding does aXichem AB Class A have?
aXichem AB Class A has 59,114,906 shares outstanding.
What happened to aXichem AB Class A’s price movement after its last earnings report?
aXichem AB Class A reported an EPS of -€0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of aXichem AB Class A?
Currently, no hedge funds are holding shares in DE:A6X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
aXichem AB Class A
aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, an natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; and aXiphen-feed, a solution for enhanced health for chickens, hens, pigs, and piglets. The company was incorporated in 2007 and is based in Malmö, Sweden.
Technical Analysis
Nexam Chemical Holding AB
―
―
Svenska Aerogel Holding AB
―
OrganoClick AB
―
XP Chemistries AB
―